RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Furthermore, it resulted in tumours with reduced levels of cysteine-dependent metabolites (hypotaurine) and increased levels of ophthalmic acid, which is synthesized in the absence of cysteine 32,33 (Fig
Nat Rev Gastroenterol Hepatol 2013;10:57584
However, it was the combined treatment of Vit C and CoQ10 that notably restored CAT activity to levels comparable to the control group
Timing Baseline Marker Lipid panel Why it matters Adds cardiometabolic context during body-composition or growth-pathway research
Uses: Provides a more efficient delivery system for antioxidant support and detoxification, offering quicker and more potent effects compared to standard oral forms
